SynDevRx Publishes Data On Evexomostat, Establishes New Metabo-Oncology Treatment Modality
Feb. 20, 2026: SynDevRx today announced the publication of a seminal research article in Frontiers in Oncology detailing the anti-tumor and systemic metabolic improvements of its lead investigational therapy, evexomostat in pre-clinical models of obesity-accelerated cancer.
Siddhartha Mukherjee: Metabolism is the next frontier in cancer treatment
Metabolism is where ecology meets oncology. A tumor shares and competes for nutrients with its microenvironment. It burns different fuels in the liver than in the lungs. It shifts when a PI3K inhibitor raises insulin, and it shifts again if hyperglycemia follows steroids.
Aretha-1 Initial Efficacy and Safety Data in mTNBC Patients To Be Presented at SABCS
Safety Run-in Cohort Results Show Anti-tumor Activity Plus Systemic Metabolic Improvements with Evexomostat Plus Eribulin in Late-line Metastatic TNBC Patients to be Presented at SABCS 2025
The Influence of GLP-1 Receptor Agonists on Five-Year Mortality in Colon Cancer Patients
Using data from the University of California Health Data Warehouse, 6,871 patients were analyzed. Five-year mortality was 15.5% for GLP-1 RA users compared to 37.1% for non-users. Analyses showed significantly lower odds of five-year mortality with GLP-1 RA use (OR = 0.38, 95% CI: 0.21-0.64). This benefit persisted after adjusting for confounders, including disease severity, […]
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.
Growing research suggests various ways weight loss drugs could have an impact in cancer care.
The Role of Insulin Resistance in Cancer
Insulin resistance is a condition, common in obesity and type 2 diabetes, where the body’s cells do not respond properly to insulin, a hormone that controls blood sugar. This review explains how this metabolic problem is a significant risk factor for several major cancers, including those of the breast, liver, and endometrium. The high levels […]
Obesity-Cancer Link: It’s Worse Than You Think
From WebMD: Cancer deaths are dropping overall, but not the ones linked to obesity. That’s what mounting evidence now shows. A sweeping new report on U.S. cancer trends, published in April, revealed that cancers linked to obesity are becoming more common. Another study, presented in July at the Endocrine Society Annual Meeting in San Francisco, found that deaths from […]
Obesity-associated cancers tripled nationwide over past two decades
SAN FRANCISCO—Cancer deaths linked to obesity have tripled in the United States over the past two decades, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. The study, which examined more than 33,000 deaths from obesity-associated cancers, revealed sharp increases in cancer deaths, especially among […]
Evexomostat Phase 1 Clinical Safety Study in Late-Stage Cancer Patients
2025 Cornelius A phase 1 safety study of evexomostat in patients with late-stage cancer